Dirk Busch, MD, is a Professor at the Technical University of Munich (TUM) where he is the director of the Institute for Medical Microbiology, Immunology and Hygiene. Dirk has published extensively on T cell engineering for immunotherapy. 

He co-founded two super successful companies: "Stage Cell Therapeutics" (sold to Juno, which was later sold to Celgene, which was later sold to BMS) and "T cell factory" (sold to Kite, which was later sold to Gilead).

Over the last 17 years, Dr Carmi has focused on studying how tumor-infiltrating macrophages and dendritic cells interact with T cells and with the surrounding stroma to promote tumor progression and escape immunity. He published over 35 peer-review papers and five patents and is a co-founder in Bolt Therapeutics, which raised over a 100 million US dollars and is now in a Phase I clinical trial. Since 2016 is has is own group in Tel Aviv university. His team published a number of papers including in the Journal of Clinical Investigation a paper describing a novel subset of T cells expressing FcgRI. Based on this discovery we formed a start-up company, which raised over one million US dollars and develops a universal CAR T cell for solid tumors.

Dr. Noam Diamant is the co-founder and CEO of Noga Therapeutics, a gene therapy company focusing on lentiviral vectors. Noam is a biopharma professional with a strong scientific background and extensive knowledge and experience in intellectual property and in cell and gene therapy. Prior to Noga Therapeutics, he co-founded Emendo biotherapeutics, a company that develops next generation gene editing tools for genetic disorders and Ingenium IP a business IP consultancy firm that provides IP strategy and management services to biopharma companies. Dr. Diamant holds a PhD in the field of DNA damage repair from the Weizmann Institute.

Tal Dvir is a Professor at Tel Aviv University, Israel. He obtained his B.Sc. (2003) and Ph.D (2008) degrees from the faculty of Engineering at Ben-Gurion University of the Negev in Israel. His Ph.D research focused on cardiac tissue engineering and regeneration.  Tal continued his postdoctoral studies in the laboratory of Prof. Robert Langer in the Department of Chemical Engineering at MIT. His postdoc research focused on advanced materials for tissue engineering and regeneration. On October 2011 Tal was recruited by the Department of Biotechnology and the Center for Nanotechnology at Tel Aviv University to establish the Laboratory for Tissue Engineering and Regenerative Medicine. In 2013, Tal joined the newly established Department of Materials Science and Engineering at Tel Aviv.

Tal’s lab designs and develops smart biomaterials and nanotechnologies for engineering complex tissues and organs. This includes the heart, brain, spinal cord, intestine, eyes and more.  Tal has published numerous high impact papers and received numerous awards and prizes. He is also an inventor of numerous patents.

Tal is currently the director of the Tel Aviv University Center for Nanoscience and Nanotechnology and the founding director of the Sagol Center for Regenerative Biotechnology.

Dr. Globerson Levin earned an MSc (2006) in Cell Biology, at Tel Aviv University and PhD (2011) at the Weizmann Institute, where she studied under Prof. Zelig Eshhar supervision. Her PhD focused on developing the CAR T cell therapy towards solid tumor. From 2013-Today, she is a senior scientist and leading the Immunology Research lab. at Tel Aviv Sourasky Medical Center.

Dr. Globerson Levin research has been focused on developing immunotherapy treatment using the chimeric antigen receptor (CAR) concept. Her effort today is overcoming the immunosuppressive environment, overcoming toxicity related to the treatment and developing new methods to redirect CAR T toward the tumor site. She developed a dual CAR T cell treatment towards multiple myeloma, which is now moving ahead to a clinical trial. She was involved in the establishment of the immunotherapy center at TASMC (I-ACT), which will be treating patients using cell therapy.

Dr. Globerson received with Eshhar several grants including the ROI/NIH, CRBC, ISF and ISF, Kamin, and Persol foundation grant that were selectively given to her. She also possess several patents related to CAR T inventions.

Erez Levanon is a full professor at the faculty of Life sciences of Bar-Ilan University where he is the head of the genomic research lab. He received his PhD from Tel-Aviv University after graduating the Adi Lautman Interdisciplinary Program and was a postdoctoral research follow at the genetics department of Harvard Medical School. Prior to that, he was a senior scientist in Compugen LTD. He has published over 80 research manuscripts and won several awards and fellowships. His main contribution is in the study of RNA and DNA editing.

Prof. Reubinoff is a full Professor of Obstetrics and Gynecology and serves as Chairman of the Department of Obstetrics and Gynecology at Hadassah University Medical Center, Jerusalem, Israel. He is also the director of the Sidney and Judy Swartz Embryonic Stem Cell Research Center of The Goldyne Savad Institute of Gene Therapy at Hadassah. He has founded and serves as the Chief Scientific Officer (CSO) of Cell Cure Neurosciences Ltd. 

The major focus of Prof. Reubinoff’s research has been human embryonic stem cells (hESCs).  He has been among the world pioneers in deriving ES cell lines from human embryos. 

Prof. Reubinoff is mainly interested in the development of the technology that may eventually allow the exploitation of hESCs for regenerative medicine. Towards this goal, he developed hESC lines that are suitable for clinical transplantation use, and further derived progeny from these hESC lines for Cell Therapy in neural and retinal degenerative disorders.

Prof. Ronit Satchi-Fainaro (Ph.D.) is a Full Professor at Tel Aviv University, where she is head of the Cancer Research & Nanomedicine Laboratory, Director of the TAU Kahn 3D BioPrinting Initiative, Director of Tel Aviv University Cancer Biology Research Center and holds the Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies. She served as Chair of the Department of Physiology & Pharmacology at the Sackler Faculty of Medicine (2014-2018), as President of the Israeli Controlled Release Society (CRS) (2010-2015), Chair of IACUC of Tel Aviv University (2013-2017). She received her B.Pharm. from the Hebrew University in Jerusalem in 1995 and her Ph.D. (Summa Cum Laude) in Polymer Chemistry and Cancer Nanomedicine from the University of London in 1999 with Prof. Ruth Duncan. She then spent four years as Postdoctoral Research Fellow at Harvard University and Children’s Hospital Boston working with Prof. Judah Folkman on Vascular and Cancer Biology. In 2003, she was appointed Instructor in Surgery at Boston Children’s Hospital and Harvard Medical School. She joined Tel Aviv University in 2006. She serves on the Board of Directors of Teva Pharmaceutical Industries, Board of Governors of Tel Aviv University, Member of 8400- The Health network, member of the Scientific Advisory Board of the Blavatnik Center for Drug Discovery, the Israel Cancer Association, the Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR, Barcelona, Spain), The Rothschild Fellowships Committee, several VCs and editorial boards of scientific journals.

Her multidisciplinary research laboratory focuses on basic research elucidating the mechanisms underlying the switch from cancer dormancy leading to the discovery of new molecular targets to interrupt tumor-host interactions. Her approach is followed by the design of highly-selective targeting molecules integrating biology, chemistry, medicine, bioinformatics and nanotechnology to selectively guide drugs into pathological sites. Throughout, she has maintained an interest in understanding the biological rationale for the design of nanomedicines suitable for transfer into clinical testing. She published more than 120 manuscripts, 13 book chapters, edited 2 books, is named inventor on 60 patents, some of which were licensed to Pharmaceutical and Biotech companies, and has delivered over 500 lectures worldwide. Her students are pursuing careers in academia, industry and government. She is a founder of a spin-off company and is actively engaged in translational research with several industry partners and in science outreach. She was awarded numerous prestigious grants and prizes among them Fulbright, Rothschild, Wingate, Alon, Young Investigator Award of the European Association for Cancer Research, JULUDAN Prize for the Advancement of Technology in Medicine, the 2013 Teva Pharmaceutical Industries Founders Award for the Discovery of new molecular mechanisms and targets that would lead to new therapeutic approaches, The 2019 CRS Translational Research Award, The 2020 Youdim Family Prize for Excellence in Cancer Research, The 2020 Kadar Family Award for Outstanding Research, the 2020 Michael Bruno Memorial Award and the 2020 Humboldt Foundation Bessel Research Prize. Her scientific achievements were acknowledged numerous times by inclusion in honorary lists by leading magazines (Forbes, Globes’ Woman of the Year 2019, named one of Israel’s Top 40 under 40 by The Marker, and by the Calcalist, and as one of 20 most promising Israelis by Yediot Aharonot). She was elected the 2019 Chair of the Gordon Research Conference on Cancer Nanotechnology, was awarded the 2018 Israel Cancer Research Fund Professorship, was selected to represent Israel at the 2016 Biennale in Venice on the Influence of Medicine on Architecture, and was awarded the European Research Council (ERC) Consolidator (2014-2019), Advanced (2019-2024) and Proof of Concept (PoC) (2019-2021) Grants.